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OBJECTIVES:
 
 To stimulate debate on the willingness of
purchasers to fund interventions with varying impact on
life years gained (LYG) and quality of life.
METHODS: The authors’ hypothesis is that, for two
health-care interventions (HCIs) with equal cost per qual-
ity adjusted life year (QALY) ratios, purchasers favour
the intervention that extends life, rather than the one that
improves quality of life.
RESULT: The list describes a conceptual framework for
assessing the relative benefit of a HCI according to its
ability to extend life or improve quality of life. Low LYG,
Low QALY  Limited Intervention, Low LYG, High
QALY  Lifestyle Intervention, High LYG, Low QALY 
Life Extending Intervention, High LYG, High QALY 
Optimal Intervention. If this hypothesis is correct it
means that there is a need for a new measure of health
gain that distinguishes between ‘life extending’ and ‘qual-
ity of life improving’ HCIs and that builds on the QALY.
As an interim step, the authors suggest that both QALYs
and LYG values be cited in future studies and a new ratio
be adopted. New Ratio  QALY  LYG As this ratio
tends towards 0, the HCI tends towards a ‘life extending
intervention.’ As this ratio tends towards infinity, the
HCI tends towards a ‘lifestyle intervention.’ Factors other
than QALYs and LYG influence purchasers and results
of this new ratio should be interpreted with caution.
CONCLUSIONS: LYG and QALYs are widely recog-
nized and respected measures of HCI effect and are fre-
quently used in economic evaluation. Viewed in isolation
the measures do not inform purchasers as to the nature of
the HCI effect, and a ratio of the two would help im-
prove this understanding. The authors would welcome
feedback from purchasers as to how useful this new mea-
sure would be in informing health-care resource alloca-
tion decisions.
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OBJECTIVE: The reliability of a computer program to au-
tomatically scan and interpret data from manually-coded,
data-collection forms was evaluated in a resource-utilization
study of patients undergoing total knee-replacement surgery
and receiving low molecular-weight heparin therapy to pre-
vent deep vein thrombosis.
METHODS: Detailed in-patient data was extracted by
technicians via manual chart review and recorded on 13-
page forms. To expedite the analysis, Teleform 6.2 was
used to design the data-collection form and later, to auto-
matically scan and interpret each form returned.
RESULTS: The reliability of this technology was evalu-
ated for the first 100 eligible-patient forms received. Of
all field entries, Teleform automatically processed 89.9%
without an operator verification prompt. The remaining
ambiguous fields were viewed and edited on screen by an
operator. Data for each completed form was then for-
warded to an output data set. The output data set records
were compared against screen images of the original data
forms to determine the reliability of this process. An aver-
age of 183 field entries was recorded for each patient and
scanned by Teleform. 99.0% of the fields in the output
data set matched completely with the handwritten field
entries on the original forms. This reliability varied
slightly with the type of field analyzed. Check box, date,
numeric, and alphanumeric fields had reliability scores of
100.0%, 99.8%, 99.6% and 96.5%, respectively.
CONCLUSION: This program shows promise for orga-
nizations that routinely collect information on hard-copy
forms, though the required learning curve and cost ham-
pers its value for the occasional user or for small projects.
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OBJECTIVE:
 
 The National Institute for Clinical Excel-
lence (NICE) is a UK government-funded body that re-
sponds to requests for guidance from the Department for
Health on the use of selected new and established tech-
nologies in the NHS in England and Wales. In March
2001 NICE published its “guidance to manufacturers”
for these submissions, essentially economic evaluation
guidelines for publicly-funded health-care services includ-
ing, but not restricted to, pharmaceuticals. This presenta-
tion analyzes the extent to which the NICE guidelines use
economics to contribute to the goals articulated in the
NICE documentation for health maximization and to re-
move unfairness in the availability of technologies under
a fixed NHS resource constraint.
METHODS: We analyze from an economics perspective
the problems giving rise to the need for guidelines, the
theoretical basis of the guidelines, and the implications of
the guidelines for health maximization and rectifying un-
fair availability.
RESULTS: The NICE guidelines fail to reflect important
economic aspects concerned with constrained health
maximization and unfair availability. The guidelines can-
not be expected to lead to maximization of health gain
from NHS resources and hence may fail to serve the
needs of NHS decision-makers. In addition, use of the
guidelines could result in continued expansion of expen-
ditures as predicted by economic analysis.
CONCLUSIONS: The guidelines aim to provide system-
wide solutions, based on standardized methods, to what
are essentially locally-based, non-standardized problems.
Although guidelines might be helpful in dealing with
matters of administrative process, the need for or ability
of such an approach to accommodate the intellectual
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substance of the wide range of problems, heterogeneous
populations, and differing circumstances faced by deci-
sion-makers has yet to be justified.
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OBJECTIVES:
 
 Clinical trials have demonstrated that
treatment can reduce the risk of osteoporosis-related
fractures in women over 50 years by 40%. The benefits
of treatment may be much lower due to lack of adherence
to treatment. Up to 20% of chronically ill patients fail to
initially fill their prescriptions, and 50% are noncompli-
ant after one year. We evaluated the feasibility of using a
database to estimate the relation between the occurrence
of fractures and adherence to osteoporosis medication in
actual practice.
METHODS: Major issues that were examined included:
whether there were sufficient subjects who received os-
teoporosis medication in the database; whether fracture
risk can be estimated in this population; how to deter-
mine whether a subject was covered for a given period
based on dispensing rather than prescribing data; when a
dispensing gap indicated non-persistence.
RESULTS: A community database of seven linked files
from Saskatchewan covering over 99% of its 1.1 million
residents was judged sufficiently large: 6,165 females older
than 45 were diagnosed in 2000 as ICD9 code 733, which
includes osteoporosis. Bisphosphonates were added to the
formulary in 1996. In 2000, 10,720 patients filled pre-
scriptions for the most widely used bisphosphonate and
33,585 filled prescriptions for conjugated estrogen. Physi-
cians or hospitals treated 12,765 females for fractures. Ad-
herence data were not available. A logical algorithm was
developed to determine persistence. It combined informa-
tion on minimally effective dose and maximum daily dos-
age with quantity, dose, dispensing date, drug type, and
tablet scoring, allowed for accumulation of medications
for later use, and corrected for hospitalizations.
CONCLUSIONS: The relation of fractures to adherence
with osteoporosis therapy can be studied through analy-
sis of this database using the algorithm.
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OBJECTIVES:
 
 To review and assess current measures of
caregiver burden in Alzheimer’s Disease (AD).
 
METHODS:
 
 A systematic search of MEDLINE, HEALTH-
STAR, and PUBMED databases was conducted to identify
all disease-specific and general caregiver-burden measures
used within the AD population. The accuracy and ultimate
value of a measure was assessed through three general psy-
chometric indices of performance: reliability; validity, and re-
sponsiveness. The evaluation of caregiver-burden instruments
along these psychometric properties were identified and com-
pared across measures.
RESULTS: A total of 62 articles were found to contain
background information or application of AD caregiver-
burden measures. Of these articles, ten measures were iden-
tified. Four were AD-specific and six were generic measures
used within the AD population. The available evidence of
each measure’s reliability, validity and responsiveness var-
ied. The Screen for Caregiver Burden (SCB) was the only
measure that reported reliability, construct and content va-
lidity, and responsiveness and performed well.
CONCLUSIONS: The lack of psychometric properties
reported in the majority of measures may limit the ability
to accurately assess caregiver burden and to evaluate
changes in response to interventions intended to lessen
this burden. Future validation studies of AD caregiver
measures will benefit by addressing these issues.
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OBJECTIVES: More than 40 EQ-5D have been evalu-
ated using a standardized time trade-off (TTO) protocol
in large-scale samples of the general public from the
United Kingdom (N  3395), Spain (N  979), and Ger-
many (N  339). This has created the first opportunity
to perform a large-scale comparison of TTO values be-
tween countries. This manuscript reports the mutual ef-
forts of several research groups within the EuroQol
Group to make such comparisons.
METHODS: Variation between the samples with respect to
background variables was controlled by multilevel analysis.
RESULTS: There are differences in TTO of health states:
the Spanish TTO values resemble the British, but the Ger-
man values are higher. The differences in TTO values are
larger than the small differences found in similar interna-
tional comparisons of VAS-based valuations. The differ-
ences found in the TTO can be explained in part by dif-
ferences in the distribution of background variables.
These results suggest that health is valued differently by
the three populations when measured using TTO, al-
though the differences are small. The differences found
seem to be driven by differences in the proportion and
the magnitude of negative health-state valuations. These
